Alkermes Plc Approval of LYBALVI - Conference Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Congratulations on the approval. Rich, I know you said the promotional campaign materials are currently under review. But can you give us any color in terms of how you can promote the weight claims? And I ask this, obviously, just going back to ENLIGHTEN-2, there's obviously some misconception, I'd say, maybe, out amongst the investor community. But can you also just remind us among the physicians and payers how did they view that shift in population weight gain? Just any color there, just given you have the ENLIGHTEN-2 data in the level.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Nice to see the approval. You mentioned the typical cycling through of medications by patients in these indications. But given there are other new products for schizophrenia that have an arguably much more benign side effect profile versus the older standards of care and patients might already be switching to such new products, do you think that cycling through patient niche remains as large or targetable as it has been before?